James I Geller1, Elizabeth Fox2, Brian K Turpin1, Stuart L Goldstein1, Xiaowei Liu3, Charles G Minard4, Rachel A Kudgus5, Joel M Reid5, Stacey L Berg4, Brenda J Weigel6. 1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 2. Developmental Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Children's Oncology Group, Monrovia, California. 4. Dan L, Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas. 5. Department of Oncology Research, Mayo Clinic, Rochester, Minnesota. 6. Department of Pediatrics, Masonic Children's Hospital, University of Minnesota Medical Center, Minneapolis, Minnesota.
Abstract
BACKGROUND: Axitinib is an oral small molecule that inhibits receptor tyrosine kinases vascular endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial evaluating axitinib was conducted in children with refractory solid tumors. METHODS: Axitinib was administered orally twice daily in continuous 28-day cycles. Dose levels (2.4 mg/m2 /dose and 3.2 mg/m2 /dose) were evaluated using a rolling 6 design. Serial PKs (cycle 1, days 1 and 8) and exploratory biomarkers were analyzed. RESULTS: A total of 19 patients were enrolled; 1 patient was ineligible due to inadequate time having elapsed from prior therapy. The median age of the patients was 13.5 years (range, 5-17 years). Two of 5 patients who were treated at dose level 2 experienced dose-limiting toxicities (palmar-plantar erythryodysesthesia syndrome in 1 patient and intratumoral hemorrhage in 1 patient). Frequent (>20%) grade 1 to 2 toxicities during cycle 1 included anemia, anorexia, fatigue, diarrhea, nausea, and hypertension. Nonhematological toxicities of grade ≥3 in subsequent cycles included hypertension and elevated serum lipase. PK analysis demonstrated variability in axitinib exposure, the median time to peak plasma concentration was 2 hours, and the half-life ranged from 0.7 to 5.2 hours. Exposure and dose were not found to be significantly associated with hypertension. Five patients achieved stable disease for ≤6 cycles as their best response, including patients with malignant peripheral nerve sheath tumor (1 patient), Ewing sarcoma (1 patient), hepatocellular carcinoma (1 patient), and osteosarcoma (2 patients). One patient with alveolar soft part sarcoma achieved a partial response. Kidney injury biomarkers were found to be elevated at baseline; no trends were identified. CONCLUSIONS: In children with refractory solid tumors, the maximum tolerated and recommended dose of axitinib appears to be 2.4 mg/m2 /dose, which provides PK exposures similar to those of adults.
BACKGROUND:Axitinib is an oral small molecule that inhibits receptor tyrosine kinases vascular endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial evaluating axitinib was conducted in children with refractory solid tumors. METHODS:Axitinib was administered orally twice daily in continuous 28-day cycles. Dose levels (2.4 mg/m2 /dose and 3.2 mg/m2 /dose) were evaluated using a rolling 6 design. Serial PKs (cycle 1, days 1 and 8) and exploratory biomarkers were analyzed. RESULTS: A total of 19 patients were enrolled; 1 patient was ineligible due to inadequate time having elapsed from prior therapy. The median age of the patients was 13.5 years (range, 5-17 years). Two of 5 patients who were treated at dose level 2 experienced dose-limiting toxicities (palmar-plantar erythryodysesthesia syndrome in 1 patient and intratumoral hemorrhage in 1 patient). Frequent (>20%) grade 1 to 2 toxicities during cycle 1 included anemia, anorexia, fatigue, diarrhea, nausea, and hypertension. Nonhematological toxicities of grade ≥3 in subsequent cycles included hypertension and elevated serum lipase. PK analysis demonstrated variability in axitinib exposure, the median time to peak plasma concentration was 2 hours, and the half-life ranged from 0.7 to 5.2 hours. Exposure and dose were not found to be significantly associated with hypertension. Five patients achieved stable disease for ≤6 cycles as their best response, including patients with malignant peripheral nerve sheath tumor (1 patient), Ewing sarcoma (1 patient), hepatocellular carcinoma (1 patient), and osteosarcoma (2 patients). One patient with alveolar soft part sarcoma achieved a partial response. Kidney injury biomarkers were found to be elevated at baseline; no trends were identified. CONCLUSIONS: In children with refractory solid tumors, the maximum tolerated and recommended dose of axitinib appears to be 2.4 mg/m2 /dose, which provides PK exposures similar to those of adults.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Tanzina Chowdhury; Kathryn Prichard-Jones; Neil J Sebire; Nelly Bier; Abraham Cherian; Maureen O Sullivan; Anne O'Meara; John Anderson Journal: J Pediatr Hematol Oncol Date: 2013-01 Impact factor: 1.289
Authors: M Kaya; T Wada; T Akatsuka; S Kawaguchi; S Nagoya; M Shindoh; F Higashino; F Mezawa; F Okada; S Ishii Journal: Clin Cancer Res Date: 2000-02 Impact factor: 12.531
Authors: Carmen Eicher; Alexander Dewerth; Bettina Kirchner; Steven W Warmann; Joerg Fuchs; Sorin Armeanu-Ebinger Journal: Liver Int Date: 2011-12-18 Impact factor: 5.828
Authors: John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2008-07 Impact factor: 3.167
Authors: Ezra E W Cohen; Lee S Rosen; Everett E Vokes; Merrill S Kies; Arlene A Forastiere; Francis P Worden; Madeleine A Kane; Eric Sherman; Sinil Kim; Paul Bycott; Michael Tortorici; David R Shalinsky; Katherine F Liau; Roger B Cohen Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: Brian I Rini; Bohuslav Melichar; Takeshi Ueda; Viktor Grünwald; Mayer N Fishman; José A Arranz; Angel H Bair; Yazdi K Pithavala; Glen I Andrews; Dmitri Pavlov; Sinil Kim; Eric Jonasch Journal: Lancet Oncol Date: 2013-10-18 Impact factor: 41.316
Authors: Justine N van der Beek; Janna A Hol; Aurore Coulomb-l'Hermine; Norbert Graf; Harm van Tinteren; Kathy Pritchard-Jones; Maite E Houwing; Ronald R de Krijger; Gordan M Vujanic; Kristina Dzhuma; Jens-Peter Schenk; Annemieke S Littooij; Gema L Ramírez-Villar; Dermot Murphy; Satyajit Ray; Reem Al-Saadi; Manfred Gessler; Jan Godzinski; Christian Ruebe; Paola Collini; Arnaud C Verschuur; Tony Frisk; Christian Vokuhl; Christina A Hulsbergen-van de Kaa; Beatriz de Camargo; Bengt Sandstedt; Barbara Selle; Godelieve A M Tytgat; Marry M van den Heuvel-Eibrink Journal: Int J Cancer Date: 2021-02-03 Impact factor: 7.396
Authors: Matilde Merolle; Maria Patrizia Mongiardi; Maurizia Piras; Andrea Levi; Maria Laura Falchetti Journal: Int J Mol Sci Date: 2020-02-21 Impact factor: 5.923